Blog
Featured post
Truveta Data leads a new era in cancer research
With more than 7 million oncology patient journeys spanning more than 100 cancer types, Truveta delivers an unprecedented breadth of regulatory grade data to support researchers in accelerating oncology therapy adoption and advancing critical cancer research.
ASCO 2025: Development and validation of machine learning risk prediction models for detection of early-onset colorectal cancer
Authors: Wilson Lau, PhD ⊕Truveta, Inc, Bellevue, WA,, Youngwon Kim, PhD ⊕Truveta, Inc, Bellevue, WA, Sravanthi Paras, MD ⊕Swedish Medical Center, Seattle, WA, Md Enamul Haque,...
ASCO 2025: Changes in colorectal cancer screening and detection following USPSTF expanded recommendations
Authors: Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA,...
Prostate cancer is in the headlines — and early detection has never been more important
Each year, more than 34,000 men in the U.S. die from prostate cancer. While early-stage disease is often highly treatable, outcomes still vary widely — especially by race,...
How Truveta benchmarks AI model quality for clinical concept extraction
As machine learning models increasingly assist in interpreting patient records, understanding how to properly evaluate these models becomes crucial for ensuring reliable clinical...
Truveta Data analysis shows improved outcomes with Impella support in high-risk heart procedures
A recent analysis using Truveta Data reveals that patients undergoing high-risk, non-emergency heart procedures (percutaneous coronary intervention, or PCI) with support from the...
Evaluating recent trends in early measles vaccinations in Texas
Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children...
Cancer innovation needs better data—not just better drugs
Cancer is one of the most heavily funded areas of medical research. And yet, with thousands of therapies in development and billions of dollars spent each year, many foundational...
ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease
Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Karthik Murugiah, MBBS, MHS ⊕Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT Section of...
ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA,...